$2.92
3.18%
Nasdaq, Aug 29, 10:45 pm CET
ISIN
US8776191061
Symbol
TSHA

Taysha Gene Therapies Inc Stock price

$2.92
+0.30 11.45% 1M
+1.32 82.50% 6M
+1.19 68.79% YTD
+0.77 35.81% 1Y
-0.24 7.59% 3Y
-17.08 85.40% 5Y
-17.08 85.40% 10Y
-17.08 85.40% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.09 3.18%
ISIN
US8776191061
Symbol
TSHA
Industry

Key metrics

Basic
Market capitalization
$796.6m
Enterprise Value
$525.4m
Net debt
positive
Cash
$312.8m
Shares outstanding
272.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
98.3 | 105.5
EV/Sales
64.9 | 69.6
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
44.6%
Return on Equity
-124.9%
ROCE
-30.5%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$8.1m | $7.5m
EBITDA
$-92.9m | $-98.0m
EBIT
$-94.0m | $-97.4m
Net Income
$-92.7m | $-98.9m
Free Cash Flow
$-82.5m
Growth (TTM | estimate)
Revenue
-37.1% | -9.4%
EBITDA
-18.8% | -14.8%
EBIT
-18.2% | -12.5%
Net Income
18.9% | -10.7%
Free Cash Flow
-9.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,146.5% | -1,298.3%
EBIT
-1,160.8%
Net
-1,145.0% | -1,310.2%
Free Cash Flow
-1,019.2%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
14.9%
Employees
73
Rev per Employee
$110.0k
Show more

Is Taysha Gene Therapies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Taysha Gene Therapies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Taysha Gene Therapies Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Taysha Gene Therapies Inc forecast:

Buy
94%
Hold
6%

Financial data from Taysha Gene Therapies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8.10 8.10
37% 37%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
5% 5%
386%
- Research and Development Expense 66 66
10% 10%
815%
-93 -93
19% 19%
-1,146%
- Depreciation and Amortization 1.16 1.16
14% 14%
14%
EBIT (Operating Income) EBIT -94 -94
18% 18%
-1,161%
Net Profit -93 -93
19% 19%
-1,145%

In millions USD.

Don't miss a Thing! We will send you all news about Taysha Gene Therapies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Taysha Gene Therapies Inc Stock News

Neutral
Seeking Alpha
20 days ago
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations Kamran Alam - CFO & Corporate Secretary Sean P. Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Conference Call Participants Biren N.
Neutral
GlobeNewsWire
20 days ago
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025
Neutral
GlobeNewsWire
27 days ago
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host...
More Taysha Gene Therapies Inc News

Company Profile

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

Head office United States
CEO Sean Nolan
Employees 73
Founded 2019
Website tayshagtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today